View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, Sept. 15 (HealthDay News) -- The U.S. Food and Drug Administration has approved four H1N1 influenza vaccines, according to a Sept. 15 news release issued by the agency.
The news release states that the initial lots of the vaccines are expected to be available within the next four weeks, and they will be distributed nationally after that time. Based on preliminary data from clinical studies, the four vaccines induce a robust immune response in healthy adults eight to 10 days after a single dose is given. The optimal dose in children has not yet been determined by clinical studies.
The vaccines are manufactured by CSL Limited, MedImmune L.L.C., Novartis Vaccines and Diagnostics Ltd., and Sanofi Pasteur Inc. Side effects are expected to be similar to those of seasonal flu vaccines. In clinical trials, the H1N1 vaccines have been well-tolerated. People who have severe allergies to chicken eggs -- or to any other substance in the vaccine -- should not be vaccinated, according to the release.
"Today's approval is good news for our nation's response to the 2009 H1N1 influenza virus. This vaccine will help protect individuals from serious illness and death from influenza," FDA's Commissioner of Food and Drugs, Margaret A. Hamburg, M.D., said in a statement.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top